- First Topical Anti-VEGF Eye Drop to Demonstrate both Safety and Biological Response as Monotherapy in Treatment-naïve Patients with Wet AMD - - Phase 1/2 Data Presented at OIS@AAO Support ...

Continuous growth of macular neovascularization size, as well as development of outer retina atrophy, was observed in neovascular age-related macular degeneration, even with frequent anti-VEGF ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular degeneration, but only for about 2 months after the last injection.

From June 2021 to April 2022, Sapieha and colleagues randomized 65 participants with DME and prior suboptimal response to anti-VEGF treatment to either UBX1325 (n=32) or sham (n=33).

They initiated therapy on anti-VEGF IVT between January 1, 2015, and December 31, 2019. A total of 190,345 eyes from 147,687 patients were included in the analysis.

This VEGF-Trap effectively suppresses tumor growth and vascularization in vivo, resulting in stunted and almost completely avascular tumors. VEGF-Trap-mediated blockade may be superior to that ...

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC Provided by PR Newswire Jul 30, 2025, 6:46:00 PM ...